Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCorbus Pharmaceuticals Holdings, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$1.19 | -$1.19 | -$1.19 |
| Q2 2024 | 3 | -$0.95 | -$0.95 | -$0.95 |
| Q3 2024 | 8 | -$1.45 | -$0.97 | -$1.24 |
| Q1 2025 | 5 | -$2.95 | -$0.77 | -$1.51 |
| Q2 2025 | 4 | -$1.59 | -$1.59 | -$1.59 |
| Q3 2025 | 4 | -$1.69 | -$1.69 | -$1.69 |
| Q4 2025 | 4 | -$1.81 | -$1.81 | -$1.81 |
| Q1 2026 | 3 | -$1.31 | -$1.31 | -$1.31 |
| Q2 2026 | 3 | -$1.43 | -$1.43 | -$1.43 |
| Q3 2026 | 3 | -$1.57 | -$1.57 | -$1.57 |
| Q4 2026 | 3 | -$1.73 | -$1.73 | -$1.73 |
Corbus Pharmaceuticals Holdings, Inc. Earnings Date And Information
Corbus Pharmaceuticals Holdings, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-1.15 earnings per share for the quarter, missing analysts' consensus estimates of $-0.99 by $0.16. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Corbus Pharmaceuticals Holdings, Inc. has generated $-10 earnings per share over the last year ($-10.31 diluted earnings per share) and currently has a price-to-earnings ratio of -4.09. Corbus Pharmaceuticals Holdings, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based on prior year's report dates.
Corbus Pharmaceuticals Holdings, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.99 | -$1.15 | -0.16 | $0 | $0 |
| 08/06/2024 | Q2 2024 | -$1.16 | -$3.55 | -2.39 | $0 | $0 |
| 05/07/2024 | Q1 2024 | -$1.09 | -$2.45 | -1.36 | $0 | |
| 03/20/2024 | Q4 2023 | -$1.81 | $1.35 M | |||
| 11/07/2023 | Q3 2023 | -$2.06 | -$2.27 | -0.21 | $0 | |
| 08/08/2023 | Q2 2023 | -$3.10 | -$2.05 | 1.05 | $0 | |
| 05/09/2023 | Q1 2023 | -$4.09 | -$4.47 | -0.38 | $0 | |
| 03/07/2023 | Q4 2022 | -$2.62 | $0 | |||
| 11/08/2022 | Q3 2022 | -$1.80 | -$2.15 | -0.35 | $0 | |
| 08/09/2022 | Q2 2022 | -$1.80 | -$5.96 | -4.16 | $200,000 | $0 |
| 05/10/2022 | Q1 2022 | -$2.70 | -$2.66 | 0.04 | $0 | |
| 03/08/2022 | Q4 2021 | -$2.46 | $-881,705 | |||
| 11/12/2021 | Q3 2021 | -$3.60 | -$0.52 | 3.08 | $978,000 | $97,323 |
| 08/12/2021 | Q2 2021 | -$3.60 | -$4.42 | -0.82 | $885,500 | $136,558 |
| 05/13/2021 | Q1 2021 | -$4.50 | -$4.14 | 0.36 | $647,824 | |
| 03/15/2021 | Q4 2020 | -$2.96 | $658,204 | |||
| 11/09/2020 | Q3 2020 | -$12.79 | $3.24 M | $1.23 M | ||
| 08/06/2020 | Q2 2020 | -$11.41 | -$15.47 | -4.06 | $3.39 M | $286,346 |
| 05/11/2020 | Q1 2020 | -$12.91 | -$12.84 | 0.07 | $1.76 M | |
| 03/16/2020 | Q4 2019 | -$12.33 | $2.57 M |
Corbus Pharmaceuticals Holdings, Inc. Earnings: FAQ's
When is Corbus Pharmaceuticals Holdings, Inc.'s earnings date?
Corbus Pharmaceuticals Holdings, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based off last year's report dates.
How can I listen to Corbus Pharmaceuticals Holdings, Inc.'s earnings conference
call?
The conference call for Corbus Pharmaceuticals Holdings, Inc.'s latest earnings report can be listened to online.
How can I read Corbus Pharmaceuticals Holdings, Inc.'s conference call transcript?
The conference call transcript for Corbus Pharmaceuticals Holdings, Inc.'s latest earnings report can be read online.
How much profit does Corbus Pharmaceuticals Holdings, Inc. generate each year?
Corbus Pharmaceuticals Holdings, Inc. (:CRBP) has a recorded net income of $0. Corbus Pharmaceuticals Holdings, Inc. has generated $-10.31 earnings per share over the last four quarters.
What is Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio?
Corbus Pharmaceuticals Holdings, Inc. (:CRBP) has a price-to-earnings ratio of -4.09 and price/earnings-to-growth ratio is -0.37.